1 min read
FDA Approves Roche’s Wilserdly Oral Breast Cancer Therapy
The approval is the first of two U.S. regulatory decisions expected this year for the oral therapy.

Roche announced that the U.S. Food and Drug Administration (FDA) approved Wilserdly (giredestrant), the company’s oral breast cancer therapy.
The approval is the first of two U.S. regulatory decisions expected this year for the therapy.